依替膦酸二钠抑制绝经后骨质疏松症患者骨吸收的临床研究

Clinical study on suppressing bone absorption by etidronate disodium in patients with postmenopausal osteoporosis

目的 评价依替膦酸二钠对绝经后骨质疏松症患者骨吸收的抑制作用。方法 绝经后骨质疏松症患者 32例 ,测定其腰椎、股骨颈骨密度和尿中脱氧吡啶啉的浓度。口服依替膦酸二钠2 0 0mg ,2次 d ,2周后改服钙尔奇D片 (钙 6 0 0mg及维生素D 12 5IU d) 11周 ,共 13周为一疗程 ,治疗两个疗程后复查骨密度和尿脱氧吡啶啉的浓度。结果 治疗两个疗程后 ,患者腰椎骨密度显著增高 (治疗前为 0 6 94± 0 12 4g cm2 ,治疗后为 0 72 1± 0 10 8g cm2 ,P <0 0 5 ) ,股骨颈骨密度无显著变化 (治疗前为 0 5 91± 0 117g cm2 ,治疗后为 0 6 0 2± 0 0 98g cm2 ,P >0 0 5 ) ;尿脱氧吡啶啉浓度显著降低 (治疗前为 6 6 7± 2 0 4nmol mmolCr,治疗后为 4 2 2± 1 6 3nmol mmolCr,P <0 0 1)。结论 依替膦酸二钠能有效抑制绝经后骨质疏松症患者的骨吸收。

Objective\ To study the suppressive effect of etidronate disodium on bone absorption in women with postmenopausal osteoporosis. Methods\ Thirty\|two postmenopausal osteoporotic women received etidronate disodium 200 mg twice a day in the first two weeks and calcium 600 mg a day in the next 11 weeks, then continued the same treatment once again. Bone mineral density (BMD) and urine deoxypyridinoline(DPD) were determined before and after the treatment. Results\ After treatment with etidronate disodium and calcium for 26 weeks, BMD in lumbar vertebrae increased (0\^721±0\^108 vs 0\^694±0\^124 g/cm\+2) and urine DPD decreased significantly (4\^22±1\^63 vs 6\^67±2\^04 nmol/mmolCr), but BMD in femoral neck had no change (0\^602±0\^098 vs 0\^591±0\^117 g/cm\+2). Conclusion\ Etidronate disodium can suppress bone absorption in women with postmenopausal osteoporosis.\;